Ingalls & Snyder LLC increased its position in Shire PLC (NASDAQ:SHPG) by 10.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,284 shares of the biopharmaceutical company’s stock after buying an additional 125 shares during the period. Ingalls & Snyder LLC’s holdings in Shire PLC were worth $212,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. Duff & Phelps Investment Management Co. increased its position in Shire PLC by 14.9% in the first quarter. Duff & Phelps Investment Management Co. now owns 34,473 shares of the biopharmaceutical company’s stock worth $6,004,000 after buying an additional 4,478 shares during the period. Gateway Investment Advisers LLC boosted its stake in shares of Shire PLC by 17.7% in the first quarter. Gateway Investment Advisers LLC now owns 29,806 shares of the biopharmaceutical company’s stock worth $5,193,000 after buying an additional 4,488 shares in the last quarter. Cohen Capital Management Inc. acquired a new stake in shares of Shire PLC during the first quarter worth about $155,000. Pinnacle Bank acquired a new stake in shares of Shire PLC during the first quarter worth about $101,000. Finally, Heritage Investors Management Corp boosted its stake in shares of Shire PLC by 11.8% in the first quarter. Heritage Investors Management Corp now owns 21,793 shares of the biopharmaceutical company’s stock worth $3,797,000 after buying an additional 2,295 shares in the last quarter. 20.22% of the stock is currently owned by institutional investors and hedge funds.
Shire PLC (NASDAQ:SHPG) traded down 1.62% during midday trading on Friday, hitting $145.55. 1,456,564 shares of the company traded hands. Shire PLC has a 12-month low of $144.18 and a 12-month high of $209.22. The stock’s 50-day moving average price is $160.70 and its 200 day moving average price is $171.91.
Shire PLC (NASDAQ:SHPG) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.53 by $0.20. The business had revenue of $3.75 billion during the quarter. Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. The business’s quarterly revenue was up 54.2% on a year-over-year basis. During the same period in the previous year, the firm posted $3.38 EPS. Analysts predict that Shire PLC will post $14.91 EPS for the current year.
The business also recently announced a semiannual dividend, which will be paid on Friday, October 20th. Investors of record on Friday, September 8th will be issued a dividend of $0.1527 per share. This represents a dividend yield of 0.21%. The ex-dividend date is Thursday, September 7th. Shire PLC’s payout ratio is 40.63%.
WARNING: This report was first published by BNB Daily and is owned by of BNB Daily. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.baseball-news-blog.com/2017/08/19/ingalls-snyder-llc-buys-125-shares-of-shire-plc-nasdaqshpg-updated.html.
A number of equities research analysts recently issued reports on the stock. HSBC Holdings plc cut shares of Shire PLC from a “hold” rating to a “reduce” rating in a report on Friday, May 19th. Royal Bank Of Canada set a $221.00 price objective on shares of Shire PLC and gave the stock a “buy” rating in a report on Thursday, May 18th. Sanford C. Bernstein cut shares of Shire PLC from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $209.22 to $161.09 in a report on Thursday, May 25th. BidaskClub upgraded shares of Shire PLC from a “strong sell” rating to a “sell” rating in a report on Friday, June 23rd. Finally, ValuEngine cut shares of Shire PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and fifteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $220.08.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.